Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study.

[1]  F. Montorsi,et al.  Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. , 2017, European urology.

[2]  R. Miralbell,et al.  Prognostic value of biochemical response to neoadjuvant androgen deprivation before external beam radiotherapy for prostate cancer: A systematic review of the literature. , 2016, Cancer treatment reviews.

[3]  F. Montorsi,et al.  A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. , 2016, European urology.

[4]  B. Vainer,et al.  The predictive value of ERG protein expression for development of castration‐resistant prostate cancer in hormone‐naïve advanced prostate cancer treated with primary androgen deprivation therapy , 2015, The Prostate.

[5]  D. Pfister,et al.  Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. , 2015, The Journal of urology.

[6]  M. Menon,et al.  Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study. , 2015, European urology.

[7]  C. Stief,et al.  Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. , 2014, European urology.

[8]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[9]  P. de Souza,et al.  Primary treatment of the prostate improves local palliation in men who ultimately develop castrate‐resistant prostate cancer , 2013, BJU international.

[10]  M. Dimopoulos,et al.  Time to castration resistance is an independent predictor of castration-resistant prostate cancer survival. , 2011, Anticancer research.